INTRODUCTION
The dynamics of the CD8 T cell response largely shape the overall course of viral infections. Upon antigen encounter, virus-specific CD8 T cells become activated and undergo a program of clonal expansion. This expansion phase is accompanied by cellular changes that are controlled at the transcriptional level. The induction of peripheral tissue homing receptors, downregulation of homeostatic cytokine receptors, and upregulation of effector molecules, such as granzyme B and perforin, are all components of the antiviral CD8 T cell response [1] [2] [3] . After the expansion phase, a large proportion of effector cells will die by apoptosis whereas some of the surviving CD8 T cells will go on to form memory [4] . Virus-specific memory CD8 T cells regain the capacity to proliferate in response to homeostatic cytokines, such as interleukin-7 and interleukin-15, and can persist in the absence of antigen, forming a long-lasting protective mechanism upon antigen reexposure [5, 6] .
The loss of virologic control in simian immunodeficiency virus (SIV)-infected rhesus macaques treated with CD8-depeleting antibodies highlights the critical importance of CD8 T cells in viral control [7] . Acute HIV infection follows similar dynamics of effector CD8 T cell expansion as is seen in other viral infections [8] [9] [10] . Unlike other viral infections, however, the expansion of the CD8 T cell compartment is not limited only to HIV-reactive cells, and CD8 T cell numbers typically remain elevated throughout the disease course [11, 12] . Upon control of viremia with antiretroviral therapy (ART), the expanded CD8 T cell compartment tends to contract a bit, yet remains elevated in many persons despite virologic suppression, even after many years of therapy [13 & ]. In this review, we will discuss the biologic and clinical significance of CD8 T cell persistence in HIV infection, touching upon the dynamics of their initial expansion in HIV infection, their phenotypic and functional characteristics, and the potential mechanisms that mediate CD8 T cell persistence in ART-treated HIV infection.
EVIDENCE OF BYSTANDER CD8 T CELL EXPANSION IN ACUTE HIV INFECTION
The immune response in acute HIV infection may have a considerable effect on long-term disease course. Marked activation of the CD8 T cell pool is well characterized in primary HIV infection and is partially attributed to the activation of HIV-specific CD8 T cells. Yet even under conditions of high viral replication, HIV-specific CD8 T cells only represent less than 10% of the total CD8 T cell pool and cannot account for all CD8 T cells that are seen to be activated in acute and chronic infection [14, 15] . CD8 T cells reactive to microbes other than HIV are also induced to expand during this period. Some of this may be due to the reactivation of latent pathogens, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV) [16] . Yet, CD8 T cells reactive to nonpersistent pathogens, such as influenza and adenovirus, are also induced to expand, implying that CD8 T cell expansion occurs through antigenindependent mechanisms as well [17 && ]. In contrast, in the CD4 T cell compartment, expansion of cells reactive to persistent pathogens such as herpes viruses is demonstrable, but CD4 T cell responses to nonpersistent antigens are unaffected [18] . It is not clear why bystander expansion occurs in the CD8 T cell compartment but not the CD4 T cell compartment in primary and early HIV infection although the susceptibility of activated CD4 T cells to lytic HIV infection may blunt bystander activation of CD4 T cells in this setting.
Does bystander CD8 T cell activation occur in other viral infections? In mice, the CD8 T cell response to lymphocytic choriomeningitis virus (LCMV) infection is largely antigen-driven, in which tetramer staining of virus-specific cells reveal that as many as 56% of activated CD8 T cells stain positive for a single LCMV epitope [19] . Although less is known about the early CD8 T cell response to viral infections other than HIV in humans, individuals vaccinated with smallpox and yellow fever vaccines display minimal activation of CD8 T cells specific for other pathogens, such as CMV, EBV, or influenza [20] . Whether the lack of bystander CD8 T cell activation in this setting is related to the self-limited replication of attenuated vaccine viruses versus the persistent replication of HIV is unknown. Nonetheless, it is apparent that CD8 T cell expansion during acute HIV infection is not limited to CD8 T cells that are HIV-specific. Furthermore, the broad CD8 T cell expansion that is demonstrable in early infection persists throughout the disease course [21 & ].
CIRCULATING CD8 T CELL NUMBERS REMAIN ELEVATED THROUGHOUT THE COURSE OF HIV INFECTION
In healthy individuals, the majority of circulating CD8 T cells comprise naïve and central memory CD8 T cells that coexpress CD27 and CD28. During chronic HIV infection, the CD8 T cell compartment is enriched for more mature effector and effector memory CD8 T cells that have lost CD27 and CD28 presumably as a result of antigenic exposure [12, 22] . The expanded CD8 T cell compartment in chronically HIV-infected patients exhibits characteristics of T cell exhaustion and immunosenescence, phenotypes associated with disease progression [23, 24] .
Exhaustion is characterized by a progressive loss of T cell function and develops under conditions of high antigen load during persistent viral infections, such as HIV, HCV, and EBV [25] [26] [27] . In HIV infection, exhaustion of CD8 T cells is associated with impairment of antiviral effector functions. These include limited proliferative capacity in response to antigen, reduced cytokine production, and high susceptibility to apoptosis in vivo [28] [29] [30] [31] . Functional impairments associated with CD8 T cell exhaustion are the result of signaling by inhibitory receptors expressed on the surface of CD8 T cells, such as programmed death receptor 1 (PD-1), CD160, or T cell immunoglobulin mucin-2 [32] . Importantly, some of the functional defects of T cell exhaustion can be reversed through blockade of these inhibitory receptors [29, 33] .
Persistent viral infections such as HIV are also characterized by increased CD8 T cell immunosenescence. Similar to exhaustion, T cell senescence can arise from sustained antigen exposure. Here, the many rounds of proliferation in the setting of chronic viral infection [24, 34] result in shortening of the telomeric ends of cellular DNAs. These senescent T cells are defined by expression of CD57 and loss of CD28. Like 'exhausted' CD8 T cells, senescent CD8 T cells do not proliferate in response to antigen [24] . Growth arrest in this population is related to
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Although some features of T cell exhaustion and T cell senescence are overlapping, some findings indicate that these processes can exist independently of one another [36] . For example, unlike exhausted CD8 T cells which are characterized by a progressive lack of functionality, CD57 þ senescent CD8 T cells are highly cytotoxic, and generally exhibit a much higher degree of polyfunctionality than exhausted CD8 T cells [37] [38] [39] [40] . Nevertheless, exhaustion markers can indeed be expressed on latedifferentiated senescent CD8 T cells, and microarray data indicate that senescent CD8 T cells can show gene signatures of exhaustion [41, 42] . Thus, it is likely that a senescent cell can become exhausted, yet at the same time, exhaustion and senescence can also be induced independently of one another. A description of similarities and differences between these two processes is illustrated in Fig. 1 .
PERSISTENTLY HIGH CIRCULATING CD8 T CELL NUMBERS IN TREATED HIV-INFECTED PATIENTS ARE ASSOCIATED WITH ADVERSE CLINICAL EVENTS
Despite a dramatic decay in HIV-specific CD8 T cell numbers upon ART administration [43, 44] . As CD4 T cell numbers are often lower than among controls, these patients often display inverted CD4/ CD8 ratios. A recent study examined the characteristics of CD8 T cells in patients with inverted CD4/ CD8 ratios despite sustaining CD4 T cell counts above 500 cells/ml on ART. In this study, inverted CD4/CD8 ratios were associated with higher absolute numbers of circulating transitional memory, effector memory, and terminal effector CD8 T cells [45 && ]. Patients with lower CD4/CD8 ratios also had higher absolute numbers of activated CD38 and human leukocyte antigen-DR coexpressing CD8 T cells, exhausted PD-1-expressing CD8 T cells, and senescent CD28 -CD57 þ CD8 T cells than did treated HIV-infected patients with CD4/CD8 ratios over 1.0 [45 && ]. Despite effective ART, HIV-infected patients are at a higher risk for non-AIDS morbidities and mortalities than the general population [46, 47] . Several studies have found that soluble mediators of inflammation and coagulation, such as interleukin-6, D-dimer, and soluble CD14, are independent predictors of non-AIDS morbidities and mortalities A diagram of similarities and differences between CD8 T cell exhaustion and senescence. IFNg, interferon-gamma; PD-1, programmed death receptor 1; SHP-2, tyrosine-protein phosphatase non-receptor type 11; Tim-3, T cell immunoglobulin mucin-2; TNF, tumor necrosis factor. [48] . In a recent study examining the relationship between the CD4/CD8 ratio and serious non-AIDS events, patients who experienced a morbid non-AIDS event during the time of study had lower CD4/CD8 ratios than patients who did not [49 & ]. This was the case for all types of non-AIDS events, such as stroke, non-AIDS malignancies, and ischemic heart disease [49 & ]. Noteworthy, these associations were independent of CD4 nadir or proximal CD4 T cell counts.
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To date, mechanistic evidence that links persistently high circulating CD8 T cells to the occurrence of non-AIDS morbid events is lacking. We have recently found that the expanded CD8 T cell compartment in treated HIV-infected patients is enriched for cells coexpressing the fractalkine receptor, CX3CR1, and the protease-activated receptor-1. CX3CR1 is a G-protein coupled receptor that binds CX3CL1 expressed on activated endothelial cells whereas protease-activated receptor-1, another G-protein coupled receptor, can become activated through the cleavage of the N-terminal end of the receptor by thrombin, a zymogen activated during coagulation [50,51 & ]. Thus, CD8 T cell persistence in treated HIV-infected patients may result in increased frequencies of circulating CD8 T cells that localize to endothelium and that may be activated during coagulation which is accelerated in HIV infection [52] . More studies are needed to ascertain whether the persistent CD8 T cell expansion in treated HIV infection contributes directly to the occurrence of non-AIDS morbidities and mortalities or whether it is a consequence of other events that themselves drive these clinical outcomes.
WHAT ARE THE DETERMINANTS OF CD8 T CELL PERSISTENCE IN TREATED HIV INFECTION?
The factors that underlie persistent CD8 expansion in treated HIV infection remain largely unidentified. Although residual HIV has been found in tissue sites in treated HIV-infected patients [53 && ], it is not likely that HIV antigens drive persistent CD8 T cell expansions as HIV-specific T cells decrease in frequency with initiation of ART and comprise less than1% of circulating CD8 T cells in treated HIV-infected patients [54, 55] .
Could the presence of other pathogens such as CMV be responsible for CD8 T cell persistence in treated HIV infection? Frequencies of CD8 T cells specific for the CMV epitope intermediate-early-1 protein are increased in treated HIV-infected patients [56] . Yet, the extent to which CMV-specific CD8 T cell pool contribute to the overall size of the CD8 T cell pool in treated HIV infection is still unclear, as CMV-specific CD8 T-cells comprise only a fraction of the expanded memory CD8 T cell pool in treated HIV-infected patients. Thus, other factors likely contribute to the persistence of CD8 T cells in this setting.
If not antigen, what may be responsible for CD8 T cell persistence in treated HIV infection? HIV infection, both untreated and treated is characterized by chronic inflammation. Microbial translocation through a persistently damaged gut epithelium is one potential contributor to sustained inflammation in this setting [57] [58] [59] . Importantly, gut damage sustained during the acute phase of HIV infection is not completely reversible even after ART [60] , and levels of microbial products remain increased in the systemic circulation of many ART-treated patients [58, 61] .
Microbial elements bind specific pathogenassociated molecular pattern receptors on antigenpresenting cells to induce proinflammatory cytokines; some of these can induce activation and proliferation of CD8 T cells in an antigen-independent manner [17 && ]. Interferon-a (IFN-a) can be induced by dendritic cells primed with microbial products and in mice, IFN-a has been shown to induce memory CD8 T cell proliferation in an antigen-independent fashion [62, 63] . Because IFN-a is increased systemically in untreated HIV infection and treated HIV-infected patients display type I interferon gene signatures [64, 65] , it is possible that sustained exposure to type I interferon's could contribute to CD8 T cell persistence in treated HIV infection.
Interleukin-15 is another cytokine induced by lypopolysaccharide-primed antigen-presenting cells [17 && ]. In mice, the absence of interleukin-15 led to slow attrition of memory CD8 T cells generated during acute LCMV infection [66] , indicating that interleukin-15 is important in maintaining memory CD8 T cell persistence. Indeed, a number of studies have shown in both humans and mice that interleukin-15 induces memory CD8 T cell proliferation and increases survival factors, such as B-cell lymphoma 2 [17 && ,67] . In primates, interleukin-15 administration resulted in a preferential expansion of effector memory CD8 T cells, resulting in an inverted CD4/CD8 ratio [68] , although this was not sustained after interleukin-15 administration was stopped.
Our group has shown that interleukin-15 levels are increased in lymph node histocultures of chronically infected untreated HIV-infected patients, [69] although it is not clear whether interleukin-15 expression remains increased in treated HIV infection. Recently, we and others have reported increased levels of interleukin-1b in the lymphoid tissues of untreated and ART-treated HIV-infected patients and have found that interleukin-1b can promote the expansion of memory CD4 and CD8 T cells in vitro without addition of exogenous antigen [70 && ,71 && ]. It is plausible that sustained expression of inflammatory cytokines, such as IFN-a, interleukin-1b, and interleukin-15, play a role in the profound and persistent memory CD8 T cell expansion that characterizes HIV infection.
The intrinsic properties of CD8 T cells may also contribute to their persistence in treated HIVinfected individuals. In conditions other than HIV infection that result in lymphopenia, such as sepsis or chemotherapy, homeostatic proliferation stimulates the reconstitution of CD8 T cells much faster than that of CD4 T cells [72, 73] . In addition, deuterated glucose labeling in HIV-infected patients revealed that CD8 þ T cells are much less susceptible to cell death than are CD4 T cells in vivo [74] . It remains to be determined whether those CD8 T cells that are expanded in treated HIV-infected patients persist through continued cell division. We have found that the cycling of circulating CD8 T cells in patients who have suppressed HIV replication with ART is not elevated, irrespective of whether they have restored circulating CD4 T cell numbers [75] . Thus, it is also plausible that these cells, once expanded and matured, persist durably without additional divisions.
CONCLUSION
Despite effective ART, many patients display residual immune dysregulation and remain at higher risk for non-AIDS-defining adverse clinical events. Although elevated inflammatory indices have been the most studied laboratory correlates of this increased risk, recent epidemiologic data also link CD8 T cell expansion and lower CD4/CD8 ratios to these morbidities. Although the majority of these expanded CD8 T cells are matured effector cells that are capable of inflammatory cytokine release, the cause of these expansions is not known and their mechanistic link to the morbid complications of treated HIV disease are only speculative.
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